Ergoteles LLC Buys Shares of 168,977 Affimed (NASDAQ:AFMD)

Posted by on Mar 4th, 2023

Ergoteles LLC acquired a new stake in shares of Affimed (NASDAQ:AFMD – Get Rating) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 168,977 shares of the biopharmaceutical company’s stock, valued at approximately $348,000. Ergoteles LLC owned approximately 0.14% of Affimed at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the business. Altium Capital Management LP bought a new position in shares of Affimed during the 3rd quarter valued at about $1,854,000. Knights of Columbus Asset Advisors LLC bought a new position in shares of Affimed during the 3rd quarter valued at about $307,000. Dimensional Fund Advisors LP boosted its position in shares of Affimed by 9.3% during the 3rd quarter. Dimensional Fund Advisors LP now owns 349,416 shares of the biopharmaceutical company’s stock valued at $720,000 after purchasing an additional 29,630 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Affimed by 125.4% during the 3rd quarter. Tower Research Capital LLC TRC now owns 40,918 shares of the biopharmaceutical company’s stock valued at $85,000 after purchasing an additional 22,765 shares in the last quarter. Finally, Fisher Asset Management LLC bought a new position in shares of Affimed during the 3rd quarter valued at about $827,000. Institutional investors own 61.73% of the company’s stock.

Affimed Price Performance

NASDAQ AFMD opened at $0.90 on Friday. The company has a 50 day simple moving average of $1.12 and a 200-day simple moving average of $1.74. The company has a debt-to-equity ratio of 0.07, a current ratio of 5.65 and a quick ratio of 5.63. The firm has a market capitalization of $111.30 million, a price-to-earnings ratio of -1.43 and a beta of 2.58. Affimed has a 52-week low of $0.82 and a 52-week high of $5.10.

Analysts Set New Price Targets

Several research analysts have commented on the stock. SVB Leerink decreased their target price on shares of Affimed from $10.00 to $6.00 and set an “outperform” rating for the company in a report on Monday, December 12th. StockNews.com upgraded shares of Affimed from a “sell” rating to a “hold” rating in a report on Monday, November 21st. Wells Fargo & Company decreased their target price on shares of Affimed from $8.00 to $7.00 and set an “overweight” rating for the company in a report on Monday, December 12th. HC Wainwright assumed coverage on shares of Affimed in a report on Monday, December 12th. They issued a “buy” rating and a $6.00 target price for the company. Finally, Truist Financial decreased their target price on shares of Affimed from $12.00 to $8.00 in a report on Monday, December 12th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $5.83.

Affimed Company Profile

(Get Rating)

Affimed NV engages in the discovery and development of cancer immunotherapies. It is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs.

Featured Stories

Institutional Ownership by Quarter for Affimed (NASDAQ:AFMD)

Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.